INCB 54329

Drug Profile

INCB 54329

Alternative Names: INCB-054329; INCB-54329

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours
  • Preclinical Pancreatic cancer; Prostate cancer

Most Recent Events

  • 31 Jan 2018 Incyte Corporation completes a phase I/II trial in Solid tumours and Haematological malignancies (Late stage disease, Second line therapy or greater) in USA (NCT02431260)
  • 30 Oct 2017 Adverse events data from a phase I/II trial in Solid tumours and Haematological malignancies presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 02 Apr 2017 Pharmacodynamics data from a preclinical trial in Diffuse large B-cell lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research(AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top